KOD - Kodiak Sciences • Financials

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2016	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	0	-251	-	0%	L	266	L	-286	-	-243	-41	0	-284	0	0	-	-
12/2024	0	-160	-	0%	L	150	L	-168	-	-178	-0	1	-178	0	0	-	-
12/2025	0	-208	-	0%	L	157	L	-210	-	-195	-1	178	-195	0	0	-	-

To see all financials—including updated, you must be Premium.